Enterprise Therapeutics

Enterprise Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD. The company focuses on drug discovery targeting the underlying mechanisms of mucus congestion to reduce lung infections and improve patient quality of life. Its lead candidate, ETD001, is an inhaled ENaC blocker currently undergoing clinical trials for the treatment of cystic fibrosis.